作者
Katherine A Hughes, Konstantinos N Manolopoulos, Javaid Iqbal, Nicholas L Cruden, Roland H Stimson, Rebecca M Reynolds, David E Newby, Ruth Andrew, Fredrik Karpe, Brian R Walker
发表日期
2012/6/1
期刊
Diabetes
卷号
61
期号
6
页码范围
1357-1364
出版商
American Diabetes Association
简介
11β-Hydroxysteroid dehydrogenase type 1 (11βHSD1) is a therapeutic target in metabolic syndrome because it catalyses reductase regeneration of cortisol from cortisone in adipose and liver. 11βHSD1 can also catalyze the reverse dehydrogenase reaction in vitro (e.g., if cofactor is limited). We used stable isotope tracers to test the hypothesis that both 11βHSD1-reductase and -dehydrogenase activities occur in human metabolic tissues in vivo. 1,2-[2H]2-Cortisone (d2-cortisone) was validated as a tracer for 11β-dehydrogenase activity and its inhibition by licorice. d2-Cortisone and 9,11,12,12-[2H]4-cortisol (d4-cortisol) (to measure 11β-reductase activity) were coinfused and venous samples obtained from skeletal muscle, subcutaneous adipose (n = 6), and liver (n = 4). Steroids were measured by liquid chromatography–tandem mass spectrometry and arteriovenous differences adjusted for blood flow. Data are …
引用总数
20122013201420152016201720182019202020212022202320241121613686335131